FDA approves enfortumab vedotin plus pembrolizumab for urothelial carcinoma
December 15th 2023The approval is supported by findings from the phase 3 EV-302 trial, which showed that the combination led to significant improvements in overall survival and progression-free survival compared with chemotherapy.
UGN-102 reaches nearly 80% complete response rate in low-grade intermediate-risk NMIBC
November 30th 2023Primary chemoablative therapy with the mitomycin-containing reverse thermal gel UGN-102 induced complete responses in nearly 4 out of 5 patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.
Study of imaging agent for PSMA-negative prostate cancer hits enrollment goal
November 7th 2023“Preclinical and clinical findings thus far indicate that SAR-Bombesin holds significant potential for improving the diagnosis and treatment of prostate cancer,” said lead principal investigator Andrei Iagaru, MD.
Adjuvant pembrolizumab improves overall survival in certain patients with renal cell carcinoma
November 1st 2023Adjuvant pembrolizumab improved overall survival compared with placebo in patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.